Ajla Hrle
Chief Business Officer DISCO Pharmaceuticals GmbH
Ajla Hrle, Chief Business Officer at DISCO Pharmaceuticals, brings over a decade of experience in building transformative Life Science companies, driven by the mission to positively impact patient lives. She is a recognized leader in the biotechnology sector, combining her expertise as a scientist, business professional, and board member. From 2023 to 2024, Ajla served as Head of Life Sciences at ATHOS KG, the Strüngmann Family Office. Between 2016 and 2022, she held roles at Immatics N.V., most recently as Vice President of Strategic Alliances. During this time, she completed multiple licensing transactions from early-stage to commercial, contributed to public listings, led fund and direct investments, and established Corporate Communications and Alliance Management departments. Earlier, she led technical sales in Scandinavian markets at NanoTemper Technologies GmbH. Ajla obtained her PhD from the Max Planck Institute of Biochemistry and Ludwig-Maximilians-University in Munich as a Schering Foundation Fellow.
Seminars
- How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
- How are we are validating new, and assessing novel versus de-risked targets?
- What type of clinical data would lead the field to reassess assumptions on a target?
